By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Serotonin-norepinephrine reuptake inhibitors > Levomilnacipran > Levomilnacipran Dosage
Serotonin-norepinephrine reuptake inhibitors
https://themeditary.com/dosage-information/levomilnacipran-dosage-11324.html

Levomilnacipran Dosage

Drug Detail:Levomilnacipran (Levomilnacipran [ lee-voe-mil-na-si-pran ])

Drug Class: Serotonin-norepinephrine reuptake inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Depression

Initial dose: 20 mg orally once a day for 2 days, then increase to 40 mg orally once a day
Maintenance dose: 40 to 120 mg orally once a day
Maximum dose: 120 mg/day

Comments:

  • The dose may be increased in increments of 40 mg at intervals of 2 or more days based on tolerability and efficacy.
  • Efficacy was established in trials lasting 5 weeks.

Use: Treatment of major depressive disorder (MDD)

Renal Dose Adjustments

Mild renal dysfunction (CrCl 60 to 89 mL/min): No adjustment recommended.
Moderate renal dysfunction (CrCl 30 to 59 mL/min): Maintenance dose should not exceed 80 mg/day.
Severe renal dysfunction (CrCl 15 to 29 mL/min): Maintenance dose should not exceed 40 mg/day.
End stage renal disease: Not recommended.

Liver Dose Adjustments

Data not available

Dose Adjustments

CYP450 3A4 Strong Inhibitors:

  • The dose should not exceed 80 mg once a day when used with strong CYP450 3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir).

Treatment Discontinuation:
  • Gradual dose reduction is recommended whenever possible.
  • If intolerable symptoms occur following a dose decrease or discontinuation of treatment, resuming the previous dose and decreasing the dose at a more gradual rate should be considered.

Switching from this drug to a MAO inhibitor (MAOI) MAOI intended to treat psychiatric disorders: At least 7 days should elapse after stopping this drug and starting a MAOI

Switching from a MAOI intended to treat of psychiatric disorders to this drug: At least 14 days should elapse after stopping a MAOI and starting this drug

Patients who require urgent treatment with linezolid/IV methylene blue during treatment:
  • The potential benefits must outweigh the risks of serotonin syndrome.
  • Hospitalization and other psychiatric interventions should be considered in patients requiring urgent treatment for a psychiatric condition.
  • This drug should be stopped promptly before administering linezolid/IV methylene blue.
  • Patients should be monitored for serotonin syndrome for 2 weeks OR 24 hours after the last dose of linezolid/IV methylene blue, whichever comes first.
  • Treatment may resume 24 hours after the last dose of linezolid/IV methylene blue.

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or to any of the ingredients

US BOXED WARNINGS:
SUICIDAL THOUGHTS AND BEHAVIORS:
  • Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies.
Recommendations:
  • Patients treated with antidepressants should be closely monitored for clinical worsening and for the emergence of suicidal thoughts and behaviors.
  • This drug is not approved for use in pediatric patients.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • This drug may be administered without regard to meals, but it should be taken at approximately the same time each day.
  • This drug should be swallowed whole, and should not be opened, chewed, or crushed.
  • This drug should not be taken with alcohol.

General:
  • Limitation of use: This drug is not approved for the management of fibromyalgia.
  • Patients should be reassessed periodically to determine the need for maintenance treatment and the appropriate dose for treatment.

Monitoring:
  • CARDIOVASCULAR: Regular blood pressure monitoring
  • NERVOUS SYSTEM: Signs/symptoms of serotonin syndrome
  • PSYCHIATRIC: Discontinuation symptoms; worsening and emergence of suicidal thoughts

Patient advice:
  • This drug may impair judgment, thinking, and motor skills. Driving or operating machinery should be avoided if these side effects occur.
  • Patients should be instructed to avoid abrupt discontinuation of treatment.
  • Patients, families, and caregivers should report worsening of depression, suicidal ideation, or any unusual changes in behavior, especially during early antidepressant treatment and when doses are adjusted up or down.
  • Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Frequently asked questions

  • Does Fetzima cause weight loss or weight gain?
  • Does Fetzima cause hair loss?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by